The Man Who Brought Psychedelics Into Mainstream Medicine | Rick Doblin
Rick Doblin reflects on MAPS' 40-year journey from underground advocacy to mainstream FDA recognition, driven by personal tragedy involving his grandmother's depression and FDA refusals.summaryDoblin also shares evolved perspectives on psychedelic impacts, noting they do not automatically confer political liberalism, and stresses the importance of long-term service and meaning over immediate financial gain.summaryThe transition from underground to mainstream psychedelic research was catalyzed by personal loss; Doblin attempted to use MDMA for his grandmother's depression but was blocked by the FDA's refusal of compassionate use, takeaway
